Abstract
Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, a monoclonal anti-VEGF antibody, was a rational approach to be tested in MPM. Based on the results of the Phase III IFCT-0701 mesothelioma avastin cisplatin pemetrexed study, cisplatin-pemetrexed-bevacizumab is now the accepted standard in France. The National Comprehensive Cancer Network guidelines have also included this combination as an option for standard front-line therapy. This review summarized the efficacy and safety data of bevacizumab in the treatment of patients with MPM.
Keywords:
angiogenesis inhibitor; bevacizumab; malignant pleural mesothelioma.
MeSH terms
-
Angiogenesis Inhibitors / chemistry
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use*
-
Animals
-
Antineoplastic Agents, Immunological / chemistry
-
Antineoplastic Agents, Immunological / pharmacology
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab / chemistry
-
Bevacizumab / pharmacology
-
Bevacizumab / therapeutic use*
-
Clinical Trials as Topic
-
Drug Evaluation, Preclinical
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / mortality
-
Lung Neoplasms / pathology
-
Mesothelioma / drug therapy*
-
Mesothelioma / mortality
-
Mesothelioma / pathology
-
Mesothelioma, Malignant
-
Molecular Targeted Therapy
-
Pleural Neoplasms / drug therapy*
-
Pleural Neoplasms / mortality
-
Pleural Neoplasms / pathology
-
Randomized Controlled Trials as Topic
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents, Immunological
-
Bevacizumab